Iovance Biotherapeutics (NASDAQ: IOVA) — Perfil da empresa, notícias e dados financeiros
Iovance Biotherapeutics pioneers T-cell cancer immunotherapy, focused on developing tumor-infiltrating lymphocyte technology.
Iovance Biotherapeutics
Iovance Biotherapeutics (NASDAQ:IOVA) specializes in pioneering the development of novel cancer immunotherapies. Its primary focus is on T-cell therapy, aiming to harness the power of a patient's immune system to target and eliminate cancer cells. At the forefront of Iovance’s innovative projects is the development of tumor-infiltrating lymphocyte (TIL) technology, which they believe could offer new, effective treatment options for patients with various cancer types, including melanoma, cervical, and head and neck cancers. The company is driven by a commitment to advancing its clinical programs and expanding its pipeline to provide innovative cancer treatments that improve patient outcomes.
Resumo
Operações
Produtos e/ou serviços de Iovance Biotherapeutics
- TIL (tumor infiltrating lymphocyte) therapy for melanoma, a pioneering approach using patients' own immune cells.
- LN-145, an adoptive cell transfer therapy targeting cervical and head & neck cancers.
- LN-144, a TIL-based treatment designed for patients with metastatic melanoma.
- IOV-4001, a next-generation TIL therapy focusing on optimizing and enhancing the potency against solid tumors.
- Partnership initiatives for the development of novel CAR-T therapies, aiming at broadening cancer treatment options.
- Manufacturing innovations, including the development of a streamlined and scalable process for TIL production.
equipe executiva do Iovance Biotherapeutics
- Frederick G. VogtInterim CEO, President, General Counsel, Corporate Secretary & Director
- Corleen M. RocheChief Financial Officer
- Igor P. BilinskyChief Operating Officer
- Raj K. PuriChief Regulatory Officer
- Daniel G. KirbyChief Commercial Officer
- Sara PellegrinoSenior Vice President of Investor Relations & Corporate Communications
- Tracy WintonExecutive Vice President of Human Resources
- Howard B. JohnsonChief Business Officer
- Kevin SmythExecutive Vice President of Quality
- Brian GastmanExecutive Vice President of Translational Medicine & Research
Últimas notícias sobre a Iovance Biotherapeutics
Principais indicadores financeiros
Resultados divulgados pela Iovance Biotherapeutics, em USD.
- Cap. de mercado
- 6,6 bi
- Receita (TTM)
- 325 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.7
- Dividend yield
- —
- Margem de lucro
- -89.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 263,5 mi | -398,2 mi | -391 mi | |
| 164,1 mi | -395,3 mi | -372,2 mi | |
| 1,2 mi | -460,6 mi | -444 mi | |
| 238 mil | -398,9 mi | -389,9 mi |